GERN Geron Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: GERN

Price (delayed)

$1.945

Market cap

$1.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$1.08B

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two ...

Highlights
Geron's EPS has increased by 5% from the previous quarter
Geron's equity has soared by 169% YoY but it has decreased by 2.6% from the previous quarter
The quick ratio has grown by 40% YoY but it has contracted by 28% from the previous quarter
The revenue has plunged by 79% YoY and by 30% from the previous quarter
The company's gross profit has shrunk by 79% YoY and by 30% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.geron.com
Peers: GILD STEM TECH INCY

Key stats

What are the main financial stats of GERN
Market
Shares outstanding
543.06M
Market cap
$1.06B
Enterprise value
$1.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.5
Price to sales (P/S)
3,555.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,410.2
Earnings
Revenue
$317,000
EBIT
-$166.79M
EBITDA
-$165.77M
Free cash flow
-$162.89M
Per share
EPS
-$0.35
Free cash flow per share
-$0.28
Book value per share
$0.56
Revenue per share
$0
TBVPS
$0.71
Balance sheet
Total assets
$413.02M
Total liabilities
$122.4M
Debt
$56.02M
Equity
$290.61M
Working capital
$245.7M
Liquidity
Debt to equity
0.19
Current ratio
3.75
Quick ratio
3.68
Net debt/EBITDA
-0.15
Margins
EBITDA margin
-52,294%
Gross margin
100%
Net margin
-55,138.5%
Operating margin
-57,289%
Efficiency
Return on assets
-48.4%
Return on equity
-70.3%
Return on invested capital
-59.3%
Return on capital employed
-51.5%
Return on sales
-52,616.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GERN stock price

How has the Geron stock price performed over time
Intraday
1.83%
1 week
-0.26%
1 month
8.66%
1 year
-17.93%
YTD
-19.63%
QTD
-8.25%

Financial performance

How have Geron's revenue and profit performed over time
Revenue
$317,000
Gross profit
$317,000
Operating income
-$181.61M
Net income
-$174.79M
Gross margin
100%
Net margin
-55,138.5%
The revenue has plunged by 79% YoY and by 30% from the previous quarter
The company's gross profit has shrunk by 79% YoY and by 30% QoQ
The operating margin has declined by 48% since the previous quarter
GERN's net margin is down by 45% since the previous quarter

Growth

What is Geron's growth rate over time

Valuation

What is Geron stock price valuation
P/E
N/A
P/B
3.5
P/S
3,555.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,410.2
Geron's EPS has increased by 5% from the previous quarter
Geron's equity has soared by 169% YoY but it has decreased by 2.6% from the previous quarter
The P/B is 44% below the last 4 quarters average of 6.1
The P/S is 189% above the 5-year quarterly average of 1206.5 and 19% above the last 4 quarters average of 2929.3
The revenue has plunged by 79% YoY and by 30% from the previous quarter

Efficiency

How efficient is Geron business performance
Geron's ROS has decreased by 45% from the previous quarter
GERN's ROE is up by 37% year-on-year and by 17% since the previous quarter
The ROA has grown by 18% YoY and by 11% from the previous quarter
Geron's ROIC has increased by 18% YoY and by 16% from the previous quarter

Dividends

What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GERN.

Financial health

How did Geron financials performed over time
Geron's total assets has surged by 78% YoY
The quick ratio has grown by 40% YoY but it has contracted by 28% from the previous quarter
GERN's debt is 81% smaller than its equity
Geron's equity has soared by 169% YoY but it has decreased by 2.6% from the previous quarter
GERN's debt to equity has shrunk by 63% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.